A Phase 1 interventional study of Rivaroxaban (Xarelto, BAY59-7939) and Rivaroxaban (Xarelto, BAY59-7939) in Therapeutic Equivalency, sponsored by Bayer. Completed at 1 site in Germany. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-04-22.
Sponsored by Bayer · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The drug investigated in this study is Rivaroxaban, a novel, once-daily, oral anticoagulant for the prevention (prophylaxis) of deep vein thrombosis (DVT) which may lead to a pulmonary embolism (PE) in people undergoing knee or hip replacement surgery.
The purpose of this study is to establish bioequivalence of 2 immediate-release tablet treatments with Rivaroxaban: 2*5 mg tablets and 1*10 mg tablet will be given to healthy volunteers under fasting conditions; they will be administered as single oral doses in 2 periods. Both periods will be separated by a 7-day washout phase. Thus, the bioequivalence represents the primary study objective. As a secondary objective, this treatment will be assessed in terms of safety and tolerability.
Bioequivalence will be evaluated and verified on the basis of pharmacokinetic data. Blood samples of the volunteers will be taken at specific points in time; these samples will be analyzed using various statistical methods to establish pharmacokinetic characteristics required to compare the 2 treatments. The planned treatments with Rivaroxaban will be considered bioequivalent if specific criteria defined in the study protocol are met.
The study will be conducted in one center in Germany. 28 subjects meeting the inclusion criteria will participate. They will be treated according to a single-dose, randomized, 2-way cross-over, non-placebo-controlled design.
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single oral dose of rivaroxaban administered under fasting conditions 2\*5 mg tablet in first intervention period and 1\*10 mg tablet in second intervention period (after washout period)
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Single oral dose of rivaroxaban administered under fasting conditions 1\*10 mg tablet in first intervention period and 2\*5 mg tablet in second intervention period (after washout period)
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Single oral dose of rivaroxaban administered under fasting conditions 2\*5 mg tablet in first intervention period and 1\*10 mg tablet in second intervention period (after washout period)
Single oral dose of rivaroxaban administered under fasting conditions 1\*10 mg tablet in first intervention period and 2\*5 mg tablet in second intervention period (after washout period)
Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity After Single Dose (AUC) Incl. Bioequivalence (BE) Evaluation
The AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample (AUC is defined as area under the concentration vs. time curve from zero to infinity after single (first) dose).
Time frame: 0 min, 15 min, 30 min, 45 min, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours, 24 hours, 36 hours, 48 hours and 72 hours post administration
Area Under the Plasma Concentration Versus Time Curve From Time Zero to Last Quantifiable Concentration [AUC (0-tn)] Incl. Bioequivalence (BE) Evaluation
The AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample; \[AUC (0-tn)\] is defined as AUC from time 0 to the last data point above the Lower Limit of Quantification.
Time frame: 0 min, 15 min, 30 min, 45 min, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours, 24 hours, 36 hours, 48 hours and 72 hours post administration
Maximum Observed Drug Concentration in Plasma After Single Dose Administration (Cmax) Incl. Bioequivalence (BE) Evaluation
Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.
Time frame: 0 min, 15 min, 30 min, 45 min, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours, 24 hours, 36 hours, 48 hours and 72 hours post administration
Area Under the Plasma Concentration Versus Time Curve Divided by Dose Per kg Body Weight (AUCnorm)
The AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample; AUCnorm is defined as AUC divided by dose per kg body weight.
Time frame: 0 min, 15 min, 30 min, 45 min, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours, 24 hours, 36 hours, 48 hours and 72 hours post administration
Maximum Observed Drug Concentration in Plasma After Single Dose Administration Divided by Dose Per kg Body Weight (Cmax, Norm)
Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample; Cmax,norm is defined as Cmax divided by dose (mg) per kg body weight.
Time frame: 0 min, 15 min, 30 min, 45 min, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours, 24 hours, 36 hours, 48 hours and 72 hours post administration
Mean Residence Time (MRT)
The mean residence time is the average time that the molecules introduced into the body stay in the body.
Time frame: 0 min, 15 min, 30 min, 45 min, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours, 24 hours, 36 hours, 48 hours and 72 hours post administration
Time to Reach Maximum Drug Concentration in Plasma After Single Dose (Tmax)
Tmax refers to the time after dosing when a drug attains its highest measurable concentration (Cmax). It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
Time frame: 0 min, 15 min, 30 min, 45 min, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours, 24 hours, 36 hours, 48 hours and 72 hours post administration
Half-life Associated With the Terminal Slope (t½)
Half-life refers to the elimination of the drug, i.e. the time it takes for the blood plasma concentration to reach half the concentration in the terminal phase of elimination.
Time frame: 0 min, 15 min, 30 min, 45 min, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours, 24 hours, 36 hours, 48 hours and 72 hours post administration
All participants (part.) recruited by CRS Clinical-Research-Services Moenchengladbach GmbH, Hindenburgstrasse 304 - 306, 41061 Moenchengladbach, Germany. 28 part. were planned to be enrolled.
| Milestone | Rivaroxaban (Xarelto, BAY59-7939) First 2*5 mg, Then 1*10 mg | Rivaroxaban (Xarelto, BAY59-7939) First 1*10 mg, Then 2*5 mg |
|---|---|---|
| Started | 14 | 14 |
| Participants received treatment | 14 | 14 |
| Completed | 14 | 14 |
| Not completed | 0 | 0 |
| Milestone | Rivaroxaban (Xarelto, BAY59-7939) First 2*5 mg, Then 1*10 mg | Rivaroxaban (Xarelto, BAY59-7939) First 1*10 mg, Then 2*5 mg |
|---|---|---|
| Started | 13 | 13 |
| Participants received treatment | 13 | 13 |
| Completed | 13 | 13 |
| Not completed | 0 | 0 |
The AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample (AUC is defined as area under the concentration vs. time curve from zero to infinity after single (first) dose).
| µg*hr/L | Rivaroxaban (Xarelto, BAY59-7939) 2*5 mg | Rivaroxaban (Xarelto, BAY59-7939) 1*10 mg |
|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity After Single Dose (AUC) Incl. Bioequivalence (BE) Evaluation | 1374 ± 29.3 | 1268 ± 30.7 |
The AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample; \[AUC (0-tn)\] is defined as AUC from time 0 to the last data point above the Lower Limit of Quantification.
| µg*hr/L | Rivaroxaban (Xarelto, BAY59-7939) 2*5 mg | Rivaroxaban (Xarelto, BAY59-7939) 1*10 mg |
|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve From Time Zero to Last Quantifiable Concentration [AUC (0-tn)] Incl. Bioequivalence (BE) Evaluation | 1354 ± 29.8 | 1252 ± 31.6 |
Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.
| µg/L | Rivaroxaban (Xarelto, BAY59-7939) 2*5 mg | Rivaroxaban (Xarelto, BAY59-7939) 1*10 mg |
|---|---|---|
| Maximum Observed Drug Concentration in Plasma After Single Dose Administration (Cmax) Incl. Bioequivalence (BE) Evaluation | 179.8 ± 31.1 | 161.1 ± 38.7 |
The AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample; AUCnorm is defined as AUC divided by dose per kg body weight.
| kg*hr/L | Rivaroxaban (Xarelto, BAY59-7939) 2*5 mg | Rivaroxaban (Xarelto, BAY59-7939) 1*10 mg |
|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve Divided by Dose Per kg Body Weight (AUCnorm) | 10.79 ± 33.0 | 9.957 ± 36.4 |
Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample; Cmax,norm is defined as Cmax divided by dose (mg) per kg body weight.
| kg/L | Rivaroxaban (Xarelto, BAY59-7939) 2*5 mg | Rivaroxaban (Xarelto, BAY59-7939) 1*10 mg |
|---|---|---|
| Maximum Observed Drug Concentration in Plasma After Single Dose Administration Divided by Dose Per kg Body Weight (Cmax, Norm) | 1.412 ± 35.3 | 1.265 ± 46.0 |
The mean residence time is the average time that the molecules introduced into the body stay in the body.
| hr | Rivaroxaban (Xarelto, BAY59-7939) 2*5 mg | Rivaroxaban (Xarelto, BAY59-7939) 1*10 mg |
|---|---|---|
| Mean Residence Time (MRT) | 8.874 ± 22.0 | 9.284 ± 28.2 |
Tmax refers to the time after dosing when a drug attains its highest measurable concentration (Cmax). It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
| hr | Rivaroxaban (Xarelto, BAY59-7939) 2*5 mg | Rivaroxaban (Xarelto, BAY59-7939) 1*10 mg |
|---|---|---|
| Time to Reach Maximum Drug Concentration in Plasma After Single Dose (Tmax) | 2.50 (0.75 to 3.00) | 2.50 (0.75 to 4.00) |
Half-life refers to the elimination of the drug, i.e. the time it takes for the blood plasma concentration to reach half the concentration in the terminal phase of elimination.
| hr | Rivaroxaban (Xarelto, BAY59-7939) 2*5 mg | Rivaroxaban (Xarelto, BAY59-7939) 1*10 mg |
|---|---|---|
| Half-life Associated With the Terminal Slope (t½) | 8.932 ± 48.6 | 8.721 ± 55.7 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rivaroxaban 2*5 mg (Xarelto, BAY59-7939) | — | 0/27 (0%) | 6/27 (22.2%) |
| Rivaroxaban 1*10 mg (Xarelto, BAY59-7939) | — | 0/27 (0%) | 6/27 (22.2%) |
| Event | Rivaroxaban 2*5 mg (Xarelto, BAY59-7939) | Rivaroxaban 1*10 mg (Xarelto, BAY59-7939) |
|---|---|---|
| Glutamate dehydrogenase increasedInvestigations | 2/27 | 0/27 |
| Sinus bradycardiaCardiac disorders | 1/27 | 1/27 |
| ConstipationGastrointestinal disorders | 0/27 | 1/27 |
| DiarrhoeaGastrointestinal disorders | 0/27 | 1/27 |
| DyspepsiaGastrointestinal disorders | 0/27 | 1/27 |
| FatigueGeneral disorders | 0/27 | 1/27 |
| Injection site haematomaGeneral disorders | 0/27 | 1/27 |
| ContusionInjury, poisoning and procedural complications | 1/27 | 0/27 |
| Alanine aminotransferase increasedInvestigations | 1/27 | 0/27 |
| Aspartate aminotransferase increasedInvestigations | 1/27 | 0/27 |
| Age, Continuous(Years) | Rivaroxaban (Xarelto, BAY59-7939) First 2*5 mg , Then 1*10 mg | Rivaroxaban (Xarelto, BAY59-7939) First 1*10 mg, Then 2*5 mg | Total |
|---|---|---|---|
| Mean | 31.6 ± 5.8 | 31.3 ± 10.5 | 31.4 ± 8.3 |
| Sex: Female, Male(Participants) | Rivaroxaban (Xarelto, BAY59-7939) First 2*5 mg , Then 1*10 mg | Rivaroxaban (Xarelto, BAY59-7939) First 1*10 mg, Then 2*5 mg | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 14 | 14 | 28 |
The record gives a start of Aug 2009, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2011, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rivaroxaban